Illinois Acute or Non-Chronic Conditions
The Plan will provide at least 6 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:
ALL of the following
The member's plan is issued for Illinois.
The prescription drug is being prescribed to treat a non-chronic condition.
The prescription drug is NOT a benzodiazepine or Schedule II narcotic drug.
Illinois Chronic Conditions
The Plan will provide at least 12 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:
ALL of the following
The member's plan is issued for Illinois.
The prescription drug is being prescribed to treat a chronic or long-term condition.
The prescription drug is NOT a benzodiazepine or Schedule II narcotic drug.
New Jersey Chronic Conditions
The Plan will provide at least 6 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:
ALL of the following
The member's plan is issued for New Jersey.
The prescription drug is being prescribed to treat a chronic or long-term condition.
Oklahoma Chronic Conditions
The Plan will provide at least 36 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:
ALL of the following
The member's plan is issued for Oklahoma.
The prescription drug is being prescribed to treat a chronic or long-term condition.
The prescription drug is on the formulary.
The member remains on the same health plan.
ALL of the following
There are NO clinical criteria changes to the requested drug's prior authorization.
Texas Autoimmune Disease, Hemophilia, or Von Willebrand Disease
The Plan will provide at least 12 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:
ALL of the following
The member is a resident of Texas.
ONE of the following conditions
ALL of the following drug criteria
Illinois Appendix Authorization-Duration Rule
If the member's plan is issued for Illinois, authorization remains valid for the length of treatment as determined by the member's health care professional, subject to the applicable Illinois duration rule.
ALL of the following
The member's plan is issued for Illinois.
The authorization duration is the length of treatment determined by the member's health care professional, subject to the applicable Illinois authorization-duration requirements.
New Jersey Appendix Authorization-Duration Rule
Except where shorter time frames are necessary to monitor patient safety or treatment effectiveness, and with notice to the treating provider, a prior authorization for a health care service treating a chronic or long-term care condition remains valid for 180 days. The payer may not require the covered person to obtain another prior authorization for that health care service within the 180-day period.
ALL of the following
The prior authorization is for a health care service treating a chronic or long-term care condition.
The 180-day validity period is not shortened because a shorter period is necessary to monitor patient safety or treatment effectiveness, or, if shortened, the treating provider is notified.
Oklahoma Appendix Authorization-Duration Rule
If a prior authorization is required for a prescription drug used to treat a chronic condition and the enrollee remains on the same health plan, the authorization remains valid for 3 years from the date the health care provider receives the approval, subject to the applicable exclusions and exceptions.
ALL of the following
The prescription drug is used to treat a chronic condition.
The enrollee remains on the same health plan.
The authorization has not been affected by a clinical-criteria change, removal of the generic prescription drug from the formulary, or movement of the prescription drug to a less preferred formulary tier.
The prescription drug is not an opioid, a controlled substance prohibited from being dispensed without a prescription under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. Section 301 et seq., as amended, or a drug for the treatment of weight loss.
Texas Appendix Annual Prior Authorization Limitation
A health benefit plan issuer providing prescription drug benefits may not require an enrollee to receive more than one prior authorization annually for a prescription drug prescribed to treat an autoimmune disease, hemophilia, or Von Willebrand disease, subject to the exclusions below.
ALL of the following
The prescription drug treats ONE of the following
The annual prior authorization limitation is not excluded by the applicable Texas statutory exceptions.
For Illinois non-chronic conditions, the 6-month authorization duration does not apply to benzodiazepines or Schedule II narcotic drugs. An acute-condition exception applies when the drug's prescribing information specifies a duration that aligns with the duration in the applicable class-, drug-, or indication-specific clinical guideline; in that case, the clinical-guideline duration is used.
For Illinois chronic conditions, the 12-month authorization duration does not apply to benzodiazepines or Schedule II narcotic drugs. An exception applies when the drug's prescribing information specifies that it is administered as a one-time treatment or has another specified duration; in that case, the duration in the applicable class-, drug-, or indication-specific clinical guideline is used if aligned with the prescribing information.
For Oklahoma's 36-month authorization duration, exclusions and limitations apply to non-formulary drugs, changes to the member's health plan, clinical-criteria changes, removal of a generic prescription drug from the formulary, movement of a prescription drug to a less preferred formulary tier, opioids, controlled substances prohibited from being dispensed without a prescription under the Federal Food, Drug, and Cosmetic Act, and drugs used for the treatment of weight loss. A chronic-condition exception applies when the drug's prescribing information specifies a one-time treatment or other specified duration; the applicable class-, drug-, or indication-specific clinical-guideline duration is then used if aligned with the prescribing information.
For Texas's 12-month authorization duration, exclusions apply to opioids, benzodiazepines, barbiturates, carisoprodol, prescription drugs with a typical treatment period of less than 12 months, drugs with an FDA boxed warning for the use that require specific provider assessment, and use of a drug other than its FDA-approved use. The applicable class-, drug-, or indication-specific clinical-guideline duration is used when it is longer.
The Illinois exception does not apply to the prescription of benzodiazepines or Schedule II narcotic drugs, such as opioids.
The Oklahoma three-year authorization validity rule does not apply to prescription drugs that are opioids, controlled substances prohibited from being dispensed without a prescription under the Federal Food, Drug, and Cosmetic Act, or prescription drugs used for the treatment of weight loss. It also does not continue when clinical criteria change, the generic prescription drug is removed from the formulary, or the prescription drug is moved to a less preferred formulary tier.
The Texas annual prior authorization limitation does not apply to opioids, benzodiazepines, barbiturates, carisoprodol, prescription drugs with a typical treatment period of less than 12 months, drugs with an FDA boxed warning for the use that require specific provider assessment, or use of an FDA-approved drug in a manner other than its approved use.